基质金属蛋白酶及其抑制剂在乳腺癌中的表达  

Expression of Tissue Levels of Matrix Metalloproteinases and Their Inhibitors in Breast Cancer

作　　者：滕晓丹 张明[2] 李志高[2] 郭欣欣[1] 陈琢[1] 王洪斌[2] 

机构地区：[1]哈尔滨医科大学,黑龙江哈尔滨150040 [2]哈尔滨医科大学附属肿瘤医院乳腺外科,黑龙江哈尔滨150040

出　　处：《现代生物医学进展》2014年第29期5620-5624,共5页Progress in Modern Biomedicine

基　　金：黑龙江省教育厅科学技术研究项目(12531247);黑龙江省教育厅科学技术研究项目(12531246);黑龙江省卫生厅科研课题(2013067)

摘　　要：目的:研究基质金属蛋白酶2(Matrix Metalloproteinase-2,MMP-2),基质金属蛋白酶7(MMP-7),基质金属蛋白酶9(MMP-9),膜型基质金属蛋白酶(Membrane Type-1 Matrix Metalloproteinase,MT1-MMP),金属蛋白酶组织抑制剂1(Tissue Inhibitor of Metalloproteinase,TIMP-1),金属蛋白酶组织抑制剂2(TIMP-2)在乳腺癌组织中mRNA的表达,及与临床病理变量之间的关联。方法:采用150例乳腺癌患者的组织样本。使用半定量逆转录-聚合酶链反应(RT-PCR)法来测定肿瘤组织和正常乳腺组织中MMP-2,MMP-7,MMP-9,MT1-MMP,TIMP-1和TIMP-2的mRNA表达。结果:MMP-2,MMP-7,MMP-9,MT1-MMP,TIMP-1和TIMP-2在乳腺癌中的mRNA表达显著高于正常组织。结论:MMP-2,MMP-7,MMP-9,和MTI-MMP的表达增加和临床病理参数之间的关联,可以用来预测乳腺癌的侵害行为。Objective： To investigate mRNA expression of MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 in human breast cancer tissues, and the relationship between their expression and clinicopathological variability. Methods： Breast tissue samples from 150 patients with breast cancer were available in this study. Semiquantitative reverse transcriptase-polymerase chain reaction （RT-PCR） was carried out on tumor and normal tissues to determine mRNA expression for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2. Results： The expression of MMP-2, MMP-7, MMP-9, MT1-MMp, TIMP-1, and TIMP-2 mRNA in the breast cancer was significantly higher than that in the normal tissue. In terms of tumor size and lymph node metastasis of breast cancer, the differences in MMP-2, MMP-7, MMP-9, and MT1-MMP mRNA expression levels were significant. Conclusions： The relationship between the increased expression of MMP-2, MMP-7, MMP-9, and MTI-MMP and clinicopathological parameters reflects a role in predicting the aggressive behavior of breast cancer.

关 键 词：乳腺癌 基质金属蛋白酶 半定量RT-PCR 金属蛋白酶组织抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]